Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, With an Open-label Extension
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Encukalner (Primary) ; Antiepileptic drugs
- Indications Partial epilepsies; Seizures
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Acronyms X-TOLE
- Sponsors Xenon Pharmaceuticals
- 17 Apr 2024 Planned End Date changed from 1 Oct 2026 to 1 Oct 2028.
- 16 Apr 2024 According to a Xenon Pharmaceuticals media release, interim data and overview of the impact of disease severity on responder rates in the X-TOLE study will be presented at the American Academy of Neurology 2024 Annual Meeting.
- 08 Jan 2024 According to a Xenon Pharmaceuticals media release, this has now collected over 500 patient years of data and has been extended from five to seven years.